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of the right coronary artery distal to the SES (Fig. 2). This
improved following intracoronary nitrate administration (Fig. 3).
As we believed the severe spasm in this region to be the cause of
the earlier ventricular fibrillation, we elected to deploy a paclitaxel-
eluting stent (Taxus Express, Boston Scientific, Marlborough,
Massachusetts) to cover the vasospastic arterial segment (Fig. 4).
An excellent angiographic result was achieved, and the patient has
remained asymptomatic at follow-up.
This case illustrates that occlusive coronary spasm may
develop after drug-eluting stent deployment with potentially
life-threatening consequences. We can only speculate whether the
abnormal vasomotion in the arterial segment distal to the SES was
attributable to a local effect of sirolimus on endothelial function
(3), or to late endothelial dysfunction following brachytherapy (4).
The history of prior treatment of the vessel with paclitaxel may also
be relevant. Nonetheless, the potential for drug-eluting stents to
unfavorably alter coronary vasomotion is worthy of further study.
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REPLY
Regarding our recent study in JACC (1), we would like to thank
Drs. Kipshidze and Leon for the clarifying arguments on the
effects of sirolimus and paclitaxel on endothelial cells. We agree
that endothelial dysfunction and incomplete vascular healing may
play a key role in the development of peristent lesions and late stent
thrombosis after drug-eluting stent (DES) implantation, although
this link has not been established so far. We can only support the
need for inclusion of functional studies before introduction of new
DESs in order to identify potential negative effects on endothelial
recovery and vascular healing.
Figure 2. Development of occlusive coronary artery spasm.
Figure 3. Improved appearances following intracoronary nitrate.
Figure 4. Final angiographic result following Taxus stent deployment.
1912 Correspondence JACC Vol. 47, No. 9, 2006
May 2, 2006:1904–17
The observation by Dr. Wheatcroft and colleagues of life-
threatening coronary artery spasm following sirolimus-eluting
stent deployment is impressive and underscores the important role
of vasomotor function after stent implantation. A recent report
demonstrated severe multivessel spasms and aborted sudden car-
diac death 10 h after paclitaxel-eluting stent implantation (2). A
similar phenomenon has been described after high-dose intracoro-
nary beta-radiation by Scheinert et al. (3), who concluded that
vasoconstriction is a frequent finding a few minutes after beta-
radiation and may be due to acute radiation-induced endothelial
dysfunction.
These two letters underline the key role of re-endothelialization
for maintaining a normal vascular function after stent implantation
or intracoronary radiotherapy.
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Preventing Type 2 Diabetes
Mellitus With Angiotensin
Blockade: Is it Clinically Relevant?
Diabetes mellitus is a serious, costly, and increasingly common
disease. In light of the dramatic epidemic of type 2 diabetes and its
adverse prognostic implications, strategies to prevent or delay this
major health problem are of paramount importance.
Abuissa et al. (1), in a meta-analysis of 12 recent randomized
controlled clinical trials that enrolled patients with hypertension,
chronic heart failure, or coronary heart disease, showed that
angiotensin-converting enzyme (ACE) inhibitors and angiotensin
receptor blockers (ARBs) produced a highly significant 25%
reduction (95% confidence interval [CI], 18% to 31%) in the
incidence of new-onset diabetes when compared to placebo,
diuretics, beta-blockers, or calcium channel antagonists. Apart
from some limitations (e.g., new-onset diabetes as secondary end
point or as post hoc analysis; open-blinded end point design in
some trials; higher proportion of patients receiving drugs that
increase insulin resistance such as diuretics and beta-blockers in
the comparator groups; and absence of standardization for serial
testing of blood glucose levels), the investigators concluded that
the use of an ACE inhibitor or ARB should be considered in
patients with prediabetic conditions such as metabolic syndrome,
hypertension, impaired fasting glucose, family history of diabetes,
obesity, congestive heart failure, or coronary heart disease.
However, focusing solely on the relative risk (RR) reduction and
utilizing a surrogate marker (prevention of a fasting plasma glucose
126 mg/dl at two different visits in patients with no diabetes at
the time of presentation) make it difficult to estimate the real
benefit of the proposed intervention.
On the basis of the Abuissa et al. (1) meta-analysis, despite a
significant RR reduction of 25%, the absolute risk difference between
an ACE inhibitor or an ARB and the other agents was only 3.1 cases
per 1,000 patient-years (decreasing from 17.4 to 14.3 per 1,000
patient-years), which means that 323 patients (1/0.0031) must be
treated for one year to prevent the new onset of one case of diabetes
mellitus. Moreover, it is important to mention that the final goal of
the inhibition of the renin-angiotensin-aldosterone system in this
particular situation is to prevent the diabetes-related morbidity and
mortality rather than merely the diagnosis of diabetes. If one assumes
that the risk of any diabetes-related macrovascular or microvascular
complication is about 46 per 1,000 patient-years for newly diagnosed
patients with type 2 diabetes (2), the number needed to treat (NNT)
per year in order to prevent not only the development of type 2
diabetes mellitus but also any one of its subsequent complications
increases to 7,013 [(1/0.0031) (1/0.046)]. Even with a longer-term
follow-up, let us say 10 years, given the time frame from onset of
diabetes to diabetes-related complications, the NNT to prevent a
clinical event would be extraordinarily high.
Needless to say, this type of analysis does not contemplate the
already proved beneficial effects of ACE inhibitors and ARBs (by
other mechanisms) on the reduction of major vascular events in
certain conditions such as heart failure or after myocardial infarc-
tion. Of note, in another recent meta-analysis (3), ACE inhibitors
or ARBs decreased patients’ odds of developing new-onset type 2
diabetes but did not reduce the odds of mortality, cardiovascular,
or cerebrovascular outcomes among patients with hypertension.
Therefore, instead of searching for pharmacological therapies that
are statistically attractive but will never be clinically relevant or
cost-effective, prevention of diabetes mellitus should be fundamen-
tally approached by reducing the patient’s weight and increasing
his or her physical activity (4,5).
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